Juliya Nikolaevna Vinogradova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Juliya Nikolaevna Vinogradova has a total of 109 co-authors. Here are the top co-authors by number of shared publications:
- Nikolay V. Ilyin
A.M. Granov Russian Research Center of Radiology and Surgical Technologies
13 shared publications - Artem V. Kartashev
A.M. Granov Russian Research Center of Radiology and Surgical Technologies
5 shared publications - Anastasiya S. Butrimova
Russian Scientific Centre of Radiology and Surgical Technologies named after Academician A.M. Granov of the Ministry of Health of Russia
4 shared publications - Denis Vladimirovich Zaslavsky
Saint-Petersburg State Pediatric Medical University
4 shared publications - Luisa I. Korytova
Russian Scientific Centre of Radiology and Surgical Technologies named after Academician A.M. Granov of the Ministry of Health of Russia
4 shared publications - Maria I. Zelianina
Granov Russian Research Center of Radiology and Surgical Technologies
4 shared publications
Latest Publications
- Open Access
- 5 October 2026
- Published by Non-profit partnership Society of Interventional Oncoradiologists in Journal of oncology: diagnostic radiology and radiotherapy
- Vol. 9 (3) , 49-59
Diagnostic Significance of MRI in the Assessment of Meningiomas after Stereotactic Radiosurgery: Morphological Features and Dynamics of Changes
Purpose : To improve the efficiency of diagnostic monitoring of patients with meningiomas after stereotactic radiosurgery. Materials and methods : This retrospective, single-center study included 50 patients with meningiomas who underwent stereotactic radiosurgery (SRS) using the Gamma Knife ICON (Elekta). The mean age was 64.9 ± 11.6 years. Skull base meningiomas were detected in 21 of 50 patients (42.0 %), parasagittal meningiomas in 18 of 50 (36.0 %), and convexital meningiomas in 11 of 50 (22.0 %). Histological verification (based on the results of the previous resection) was performed in 24 patients: Grade I — 10, Grade II — 8, Grade III — 6. Follow-up MRI examinations were performed 3, 6, and 12–14 months after SRS. For each tumor, changes in area (using the RANO criteria) and volume were determined; agreement between the methods was assessed using the Cohen’s kappa coefficient. In addition, qualitative MRI features were assessed: contrast enhancement pattern, perifocal edema, margin clarity, and the presence of new lesions. Results : According to the volume classification, progression was observed in 12 of 50 patients (24.0 %; 95 % CI: 14.3–37.4), stabilization in 32 of 50 (64.0 %), and response in 6 of 50 (12.0 %). According to the RANO criteria: 10 of 50 (20.0 %) / 21 of 50 (42.0 %) / 19 of 50 (38.0 %), respectively. The agreement between the two methods was 68.0 % (Cohen’s kappa 0.498). The grade of malignancy was significantly associated with progression (chi-square p = 0.043; pairwise Grade I vs III: p = 0.035); localization was not (p = 0.84). A combination of qualitative MR features demonstrated high diagnostic efficacy: persistent heterogeneous contrast enhancement at 12-14 months, combined with pathological dynamics of perifocal changes. Each feature was characterized by a different sensitivityspecificity ratio: the appearance of new lesions — Sn 41.7 %, Sp 100 %; perifocal edema — Sn 41.7 %, Sp 92.1 %; the appearance of fuzzy margins — Sn 25.0 %, Sp 100 %. Conclusion : Quantitative volumetric assessment of meningiomas after SRS proved more sensitive compared to area-based assessment (RANO), additionally identifying cases of occult progression in 2 patients (4 %). The grade of meningioma malignancy is a significant factor associated with the risk of progression; a significant difference was found between Grade I and Grade III. The location of the lesion did not affect treatment outcomes. A set of qualitative MRI features (characteristics and dynamics of contrast enhancement, perifocal edema, clarity of contours, new lesions) provides the basis for differential diagnosis of true progression and post-radiation reactions.
- 5 October 2026
- Published by Non-profit partnership Society of Interventional Oncoradiologists in Journal of oncology: diagnostic radiology and radiotherapy
- Vol. 9 (3) , 49-59
Open AccessDiagnostic Significance of MRI in the Assessment of Meningiomas after Stereotactic Radiosurgery: Morphological Features and Dynamics of Changes
Purpose : To improve the efficiency of diagnostic monitoring of patients with meningiomas after stereotactic radiosurgery. Materials and methods : This retrospective, single-center study included 50 patients with meningiomas who underwent stereotactic radiosurgery (SRS) using the Gamma Knife ICON (Elekta). The mean age was 64.9 ± 11.6 years. Skull base meningiomas were detected in 21 of 50 patients (42.0 %), parasagittal meningiomas in 18 of 50 (36.0 %), and convexital meningiomas in 11 of 50 (22.0 %). Histological verification (based on the results of the previous resection) was performed in 24 patients: Grade I — 10, Grade II — 8, Grade III — 6. Follow-up MRI examinations were performed 3, 6, and 12–14 months after SRS. For each tumor, changes in area (using the RANO criteria) and volume were determined; agreement between the methods was assessed using the Cohen’s kappa coefficient. In addition, qualitative MRI features were assessed: contrast enhancement pattern, perifocal edema, margin clarity, and the presence of new lesions. Results : According to the volume classification, progression was observed in 12 of 50 patients (24.0 %; 95 % CI: 14.3–37.4), stabilization in 32 of 50 (64.0 %), and response in 6 of 50 (12.0 %). According to the RANO criteria: 10 of 50 (20.0 %) / 21 of 50 (42.0 %) / 19 of 50 (38.0 %), respectively. The agreement between the two methods was 68.0 % (Cohen’s kappa 0.498). The grade of malignancy was significantly associated with progression (chi-square p = 0.043; pairwise Grade I vs III: p = 0.035); localization was not (p = 0.84). A combination of qualitative MR features demonstrated high diagnostic efficacy: persistent heterogeneous contrast enhancement at 12-14 months, combined with pathological dynamics of perifocal changes. Each feature was characterized by a different sensitivityspecificity ratio: the appearance of new lesions — Sn 41.7 %, Sp 100 %; perifocal edema — Sn 41.7 %, Sp 92.1 %; the appearance of fuzzy margins — Sn 25.0 %, Sp 100 %. Conclusion : Quantitative volumetric assessment of meningiomas after SRS proved more sensitive compared to area-based assessment (RANO), additionally identifying cases of occult progression in 2 patients (4 %). The grade of meningioma malignancy is a significant factor associated with the risk of progression; a significant difference was found between Grade I and Grade III. The location of the lesion did not affect treatment outcomes. A set of qualitative MRI features (characteristics and dynamics of contrast enhancement, perifocal edema, clarity of contours, new lesions) provides the basis for differential diagnosis of true progression and post-radiation reactions.
- Open Access
- 11 July 2026
- Published by Tomsk Cancer Research Institute in Siberian journal of oncology
- Vol. 25 (3) , 21-29
Assessment of the efficacy of fractionation regimes in chemoradiotherapy for inoperable locally advanced pancreatic cancer
The purpose of the study was to improve radiotherapy efficacy by optimizing fractionation regimens in patients with inoperable stage llb-lll locally advanced pancreatic cancer. Material and Methods. Treatment outcomes of 60 patients with inoperable stage llb-lll locally advanced pancreatic cancer were analyzed in a single-center comparative study with a retrospective analysis of prospectively collected clinical data. All patients received chemoradiotherapy, including 3 or more cycles of polychemotherapy (PCT) with FOLFlRlNOX or GEMCAP regimen in combination with daily split-dose radiation therapy (RT) (group A) or stereotactic radiotherapy (STRT) (group B). Results. The efficacy of daily split-dose RT was found to be higher than that of stereotactic RT Early radiation reactions corresponded to grade l-ll and were observed in both groups. lncreased levels of transaminases were the most common: in 36.7 % of patients in group A and in 46.7 % in group B (p=0.59). Nausea/vomiting was observed in 23.3 % and 40.0 %, respectively (p=0.18). An analysis of the immediate results showed that the overall rate of objective response was significantly higher in group A compared with group B (93.3 vs 70.0 %; p=0.03). However, disease progression was observed more frequently in group B than in group A patients (30.0 vs 6.7 %; p=0.042). The daily split-course regimen demonstrated significantly higher one-year (73 vs 48 %) and two-year (39 vs 15 %) overall survival rates than stereotactic RT (pConclusion. Our study demonstrated the use of combination therapy in a carefully selected group of patients with inoperable stage llb-lll locally advanced pancreatic cancer. This type of therapy allows for increased life expectancy, overall survival, and objective response rates. Moreover, continuous improvements in radiation therapy techniques help reduce the incidence of early systemic radiation reactions. Thus, the daily split-dose dose RT is more effective and can be considered the preferred RT regimen for the treatment of inoperable patients with locally advanced pancreatic cancer.
- 11 July 2026
- Published by Tomsk Cancer Research Institute in Siberian journal of oncology
- Vol. 25 (3) , 21-29
Open AccessAssessment of the efficacy of fractionation regimes in chemoradiotherapy for inoperable locally advanced pancreatic cancer
The purpose of the study was to improve radiotherapy efficacy by optimizing fractionation regimens in patients with inoperable stage llb-lll locally advanced pancreatic cancer. Material and Methods. Treatment outcomes of 60 patients with inoperable stage llb-lll locally advanced pancreatic cancer were analyzed in a single-center comparative study with a retrospective analysis of prospectively collected clinical data. All patients received chemoradiotherapy, including 3 or more cycles of polychemotherapy (PCT) with FOLFlRlNOX or GEMCAP regimen in combination with daily split-dose radiation therapy (RT) (group A) or stereotactic radiotherapy (STRT) (group B). Results. The efficacy of daily split-dose RT was found to be higher than that of stereotactic RT Early radiation reactions corresponded to grade l-ll and were observed in both groups. lncreased levels of transaminases were the most common: in 36.7 % of patients in group A and in 46.7 % in group B (p=0.59). Nausea/vomiting was observed in 23.3 % and 40.0 %, respectively (p=0.18). An analysis of the immediate results showed that the overall rate of objective response was significantly higher in group A compared with group B (93.3 vs 70.0 %; p=0.03). However, disease progression was observed more frequently in group B than in group A patients (30.0 vs 6.7 %; p=0.042). The daily split-course regimen demonstrated significantly higher one-year (73 vs 48 %) and two-year (39 vs 15 %) overall survival rates than stereotactic RT (pConclusion. Our study demonstrated the use of combination therapy in a carefully selected group of patients with inoperable stage llb-lll locally advanced pancreatic cancer. This type of therapy allows for increased life expectancy, overall survival, and objective response rates. Moreover, continuous improvements in radiation therapy techniques help reduce the incidence of early systemic radiation reactions. Thus, the daily split-dose dose RT is more effective and can be considered the preferred RT regimen for the treatment of inoperable patients with locally advanced pancreatic cancer.
- Open Access
- 10 July 2026
- Published by SPRI of Radiation Hygiene Prof. PV Ramzaev in Radiatsionnaya Gygiena = Radiation Hygiene
- Vol. 19 (2) , 18-26
Evaluation of the radioprotective efficacy of water soluble sodium salt of n-acetylcysteine in experimental studies
Although several radioprotectors have been developed, their clinical use remains limited due to toxicity, a narrow therapeutic window, and reduced efficacy when administered post irradiation. Consequently, there is a pressing need to develop novel radioprotective agents with improved safety and effectiveness. The aim of this study was to evaluate the radioprotective efficacy of water-soluble sodium salt n-acetylcysteine (NAC). Materials and Methods: The study was conducted on 252 male Wistar rats to determine the radioprotective dose of sodium n-acetylcysteine, assess the effectiveness of its prophylactic administration prior to gamma irradiation, and analyze the dynamics of hematological parameters in peripheral blood. The drug was administered intraperitoneally 1 or 3 hours before irradiation, or 1 hour after exposure. Irradiation was performed using an IGUR-1 device at a dose of 7.0 Gy (LD 95–100/30 ). The working solution of sodium n-acetylcysteine (300 mg/mL, pH 7.5) was prepared ex tempore by dissolving 3 g of the dry substance in 3 mL of distilled water, followed by the addition of 3.5 mL of 5N NaOH and titration to the required pH. Results and Discussion: Intraperitoneal administration of sodium n-acetylcysteine at a dose of 2500 mg/kg contributed to partial preservation of hematopoiesis in animals exposed to 7.0 Gy (LD 95–100/30 ), promoted maintenance of the hematopoietic cell pool, and accelerated the recovery process. Evaluation of the specific radioprotective activity showed that administration at a dose of 2000 mg/kg provided 42 % survival in animals exposed to a lethal radiation dose. Conclusion: The findings in rats demonstrate the rationale for further investigation of the pharmacodynamic properties of sodium n-acetylcysteine, highlighting its significant potential as a radioprotective agent.
- 10 July 2026
- Published by SPRI of Radiation Hygiene Prof. PV Ramzaev in Radiatsionnaya Gygiena = Radiation Hygiene
- Vol. 19 (2) , 18-26
Open AccessEvaluation of the radioprotective efficacy of water soluble sodium salt of n-acetylcysteine in experimental studies
Although several radioprotectors have been developed, their clinical use remains limited due to toxicity, a narrow therapeutic window, and reduced efficacy when administered post irradiation. Consequently, there is a pressing need to develop novel radioprotective agents with improved safety and effectiveness. The aim of this study was to evaluate the radioprotective efficacy of water-soluble sodium salt n-acetylcysteine (NAC). Materials and Methods: The study was conducted on 252 male Wistar rats to determine the radioprotective dose of sodium n-acetylcysteine, assess the effectiveness of its prophylactic administration prior to gamma irradiation, and analyze the dynamics of hematological parameters in peripheral blood. The drug was administered intraperitoneally 1 or 3 hours before irradiation, or 1 hour after exposure. Irradiation was performed using an IGUR-1 device at a dose of 7.0 Gy (LD 95–100/30 ). The working solution of sodium n-acetylcysteine (300 mg/mL, pH 7.5) was prepared ex tempore by dissolving 3 g of the dry substance in 3 mL of distilled water, followed by the addition of 3.5 mL of 5N NaOH and titration to the required pH. Results and Discussion: Intraperitoneal administration of sodium n-acetylcysteine at a dose of 2500 mg/kg contributed to partial preservation of hematopoiesis in animals exposed to 7.0 Gy (LD 95–100/30 ), promoted maintenance of the hematopoietic cell pool, and accelerated the recovery process. Evaluation of the specific radioprotective activity showed that administration at a dose of 2000 mg/kg provided 42 % survival in animals exposed to a lethal radiation dose. Conclusion: The findings in rats demonstrate the rationale for further investigation of the pharmacodynamic properties of sodium n-acetylcysteine, highlighting its significant potential as a radioprotective agent.
- Open Access
- 1 July 2026
- Published by Practical Medicine Publishing House in Clinical oncohematology
- Vol. 19 (3)
Efficacy and Safety of Various Treatment Regimens for Primary CNS Lymphoma: Results of a Retrospective Study Based on the Data from Nine Saint Petersburg Medical Institutions
BACKGROUND. In the Russian Federation, systematic evidence of treatment outcomes and prognosis evaluation in primary CNS lymphoma (PCNSL) patients is currently unavailable. AIM. To study the clinical and epidemiological characteristics as well as current medical practice and the first-line therapy outcomes in PCNSL patients. MATERIALS & METHODS. The study enrolled 127 adults with histologically verified PCNSL diagnosis treated from 2010 to 2024 at nine medical institutions in Saint Petersburg. Absolute majority (n = 119; 94 %) of them received various regimens of chemo- and/or immunochemotherapy (ICT). High-dose methotrexate (HD-МТХ) protocols were administered in 103 (87 %) cases, 86 % (n = 101) of PCNSL patients received rituximab. RESULTS. Response assessment was analyzed in 111 (87 %) patients. Objective response (OR) to the first-line therapy was 72 % (n = 80) including complete remissions in 38 (34 %) patients. With the follow-up of 12 months (range 0.4–151.1 months), the 2-year overall survival (OS) was 43 % (95 % confidence interval [95% CI] 34–54 %), and the 2-year event-free survival (EFS) was 30 % (95% CI 22–40 %). Prognostic factors included ECOG status and HD-МТХ administration. After ICT, 28 (38 %) patients with OR received radiation or high-dose therapy with autologous hematopoietic stem cell transplantation as consolidation treatment. Consolidation stage, irrespective of the chosen option, was associated with better rates of long-term survival: the 2-year OS was 78 % (95% CI 62–100 %), the 2-year EFS was 59 % (95% CI 41–84 %). CONCLUSION. The clinical profile of PCNSL patients, as revealed in this study, is generally consistent with published literature. Most patients received the treatment regimens in accordance with the international guidelines, however, in a part of them, suboptimal treatment was used. The best rates of long-term survival were reported in patients who achieved OR and subsequently received consolidation therapy.
- 1 July 2026
- Published by Practical Medicine Publishing House in Clinical oncohematology
- Vol. 19 (3)
Open AccessEfficacy and Safety of Various Treatment Regimens for Primary CNS Lymphoma: Results of a Retrospective Study Based on the Data from Nine Saint Petersburg Medical Institutions
BACKGROUND. In the Russian Federation, systematic evidence of treatment outcomes and prognosis evaluation in primary CNS lymphoma (PCNSL) patients is currently unavailable. AIM. To study the clinical and epidemiological characteristics as well as current medical practice and the first-line therapy outcomes in PCNSL patients. MATERIALS & METHODS. The study enrolled 127 adults with histologically verified PCNSL diagnosis treated from 2010 to 2024 at nine medical institutions in Saint Petersburg. Absolute majority (n = 119; 94 %) of them received various regimens of chemo- and/or immunochemotherapy (ICT). High-dose methotrexate (HD-МТХ) protocols were administered in 103 (87 %) cases, 86 % (n = 101) of PCNSL patients received rituximab. RESULTS. Response assessment was analyzed in 111 (87 %) patients. Objective response (OR) to the first-line therapy was 72 % (n = 80) including complete remissions in 38 (34 %) patients. With the follow-up of 12 months (range 0.4–151.1 months), the 2-year overall survival (OS) was 43 % (95 % confidence interval [95% CI] 34–54 %), and the 2-year event-free survival (EFS) was 30 % (95% CI 22–40 %). Prognostic factors included ECOG status and HD-МТХ administration. After ICT, 28 (38 %) patients with OR received radiation or high-dose therapy with autologous hematopoietic stem cell transplantation as consolidation treatment. Consolidation stage, irrespective of the chosen option, was associated with better rates of long-term survival: the 2-year OS was 78 % (95% CI 62–100 %), the 2-year EFS was 59 % (95% CI 41–84 %). CONCLUSION. The clinical profile of PCNSL patients, as revealed in this study, is generally consistent with published literature. Most patients received the treatment regimens in accordance with the international guidelines, however, in a part of them, suboptimal treatment was used. The best rates of long-term survival were reported in patients who achieved OR and subsequently received consolidation therapy.
- Open Access
- 5 November 2025
- Published by Autonomous non-profit scientific and medical organization - Questions of Oncology in Voprosy onkologii
- Vol. 71 (5)
Resectable Pancreatic Head Cancer in High Surgical Risk Patients: Regional Chemotherapy Combined with Radiation versus Surgical Resection
Введение. В настоящее время роль регионарной химиотерапии (РХТ) и лучевой терапии (ЛТ) у больных раком поджелудочной железы окончательно не определена. Цель. Изучить ближайшие и отдаленные результаты комбинации РХТ и ЛТ по сравнению с выполнением панкреатодуоденальной резекции (ПДР) у больных РПЖ, имеющих высокий хирургический риск осложнений и летальности. Материалы и методы. Группу исследования составили 33 больных аденокарциномой головки поджелудочной железы со стадией Т2-3N0-1М0 IB-IIВ и III классом физического статуса по классификации ASA. На первом этапе была проведена РХТ в виде химиоэмболизации (ХЭ) головки поджелудочной железы с гемцитабином и липиодолом с последующей артериальной химиоинфузией гемцтабина и оксалиплатина (схема GEMOX). На втором этапе лечения выполнена ЛТ в режиме дневного дробления дозы (4 Гр в сут.) до суммарной очаговой дозы 50 Гр. В контрольную группу включены 36 больных с аналогичными стадиями заболевания и III классом ASA, которым выполнили ПДР в многопрофильной клинике. Результаты. Госпитальной летальности после химиолучевой терапии не было. Послеоперационная летальность отмечена в группе контроля у пяти (13,9 %) больных. Осложнения III-IV степени по классификации Clavien — Dindo были отмечены только после операции (n = 15, 41,7 %) (р < 0,05). Медиана времени до прогрессирования после химиолучевого лечения составила 7,8 (ДИ: 6,9–8,4) мес., после операции — 10,7 (95 % ДИ: 7,9-15,5) мес. (p < 0,05). Медианы общей и однолетней выживаемости составляли 12,4 (95 % ДИ: 10,5-17,8) мес. и 50 % против 17,4 (95 % ДИ: 11,6-25,5) мес. и 64 % соответственно (p < 0,05). В то же время общая выживаемость, оцениваемая по умершим больным (n = 26 vs n = 28), в обеих группах не различалась: 14,1 (95 % ДИ: 11,5-16,6) мес. и 14,5 (95 % ДИ: 10,5-18,5) мес. (p < 0,05). Выводы. Несмотря на высокую летальность и большое число осложнений, хирургическая операция обеспечивает лучшие показатели выживаемости даже у ослабленных больных. Актуальной является задача выявления неблагоприятных факторов для выполнения ПДР: у таких пациентов безопасной и относительно эффективной альтернативой может быть комбинация РХТ и ЛТ в режиме дневного дробления дозы.
- 5 November 2025
- Published by Autonomous non-profit scientific and medical organization - Questions of Oncology in Voprosy onkologii
- Vol. 71 (5)
Open AccessResectable Pancreatic Head Cancer in High Surgical Risk Patients: Regional Chemotherapy Combined with Radiation versus Surgical Resection
Введение. В настоящее время роль регионарной химиотерапии (РХТ) и лучевой терапии (ЛТ) у больных раком поджелудочной железы окончательно не определена. Цель. Изучить ближайшие и отдаленные результаты комбинации РХТ и ЛТ по сравнению с выполнением панкреатодуоденальной резекции (ПДР) у больных РПЖ, имеющих высокий хирургический риск осложнений и летальности. Материалы и методы. Группу исследования составили 33 больных аденокарциномой головки поджелудочной железы со стадией Т2-3N0-1М0 IB-IIВ и III классом физического статуса по классификации ASA. На первом этапе была проведена РХТ в виде химиоэмболизации (ХЭ) головки поджелудочной железы с гемцитабином и липиодолом с последующей артериальной химиоинфузией гемцтабина и оксалиплатина (схема GEMOX). На втором этапе лечения выполнена ЛТ в режиме дневного дробления дозы (4 Гр в сут.) до суммарной очаговой дозы 50 Гр. В контрольную группу включены 36 больных с аналогичными стадиями заболевания и III классом ASA, которым выполнили ПДР в многопрофильной клинике. Результаты. Госпитальной летальности после химиолучевой терапии не было. Послеоперационная летальность отмечена в группе контроля у пяти (13,9 %) больных. Осложнения III-IV степени по классификации Clavien — Dindo были отмечены только после операции (n = 15, 41,7 %) (р < 0,05). Медиана времени до прогрессирования после химиолучевого лечения составила 7,8 (ДИ: 6,9–8,4) мес., после операции — 10,7 (95 % ДИ: 7,9-15,5) мес. (p < 0,05). Медианы общей и однолетней выживаемости составляли 12,4 (95 % ДИ: 10,5-17,8) мес. и 50 % против 17,4 (95 % ДИ: 11,6-25,5) мес. и 64 % соответственно (p < 0,05). В то же время общая выживаемость, оцениваемая по умершим больным (n = 26 vs n = 28), в обеих группах не различалась: 14,1 (95 % ДИ: 11,5-16,6) мес. и 14,5 (95 % ДИ: 10,5-18,5) мес. (p < 0,05). Выводы. Несмотря на высокую летальность и большое число осложнений, хирургическая операция обеспечивает лучшие показатели выживаемости даже у ослабленных больных. Актуальной является задача выявления неблагоприятных факторов для выполнения ПДР: у таких пациентов безопасной и относительно эффективной альтернативой может быть комбинация РХТ и ЛТ в режиме дневного дробления дозы.
- Open Access
- 23 September 2025
- Published by Non-profit partnership Society of Interventional Oncoradiologists in Journal of oncology: diagnostic radiology and radiotherapy
- Vol. 8 (3) , 9-17
Value of Radiotherapy in Complex Treatment of Locally Advanced Pancreatic Cancer
Purpose: To familiarize radiation oncologists and specialists of related specialties with various aspects of a promising, comprehensive approach to patients with locally advanced pancreatic cancer.Materials and methods: The review includes data from domestic and foreign articles found in PubMed/MEDLINE, as well as a clinical case.Results: As a clinical example, patients with locally advanced pancreatic cancer who received chemotherapy followed by radiation therapy are presented, and the immediate results of treatment are demonstrated.Conclusions: Despite the predominant role of chemotherapy and surgery in the treatment of pancreatic cancer, radiation therapy still plays an important role in the comprehensive treatment of this disease as a method that improves local control in resectable, borderline resectable, locally advanced, and recurrent pancreatic cancer. However, there is a lack of data on the methods, target volume determination, and fractionation schemes.
- 23 September 2025
- Published by Non-profit partnership Society of Interventional Oncoradiologists in Journal of oncology: diagnostic radiology and radiotherapy
- Vol. 8 (3) , 9-17
Open AccessValue of Radiotherapy in Complex Treatment of Locally Advanced Pancreatic Cancer
Purpose: To familiarize radiation oncologists and specialists of related specialties with various aspects of a promising, comprehensive approach to patients with locally advanced pancreatic cancer.Materials and methods: The review includes data from domestic and foreign articles found in PubMed/MEDLINE, as well as a clinical case.Results: As a clinical example, patients with locally advanced pancreatic cancer who received chemotherapy followed by radiation therapy are presented, and the immediate results of treatment are demonstrated.Conclusions: Despite the predominant role of chemotherapy and surgery in the treatment of pancreatic cancer, radiation therapy still plays an important role in the comprehensive treatment of this disease as a method that improves local control in resectable, borderline resectable, locally advanced, and recurrent pancreatic cancer. However, there is a lack of data on the methods, target volume determination, and fractionation schemes.
- Open Access
- 22 September 2025
- Published by ECO-Vector LLC in Russian Journal of Skin and Venereal Diseases
- Vol. 28 (4) , 381-390
Dermatoscopic methods for diagnosing radiation-induced skin reactions in patients with primary cutaneous lymphomas undergoing total skin electron beam therapy
Background: Timely diagnosis and assessment of radiation-induced skin reactions remain an important challenge in modern medicine. Imaging techniques can help standardize the clinical evaluation of radiation dermatitis. Aim: The work aimed to evaluate dermatoscopic features and confocal microscopy findings in radiation dermatitis among patients with primary cutaneous lymphomas undergoing radiotherapy, with subsequent analysis of the clinical and morphological characteristics of affected skin areas before treatment and at cumulative doses of 6 Gy, 14 Gy, and 30 Gy, based on macroscopic and dermatoscopic imaging of radiation-induced skin reactions for further comparison. Methods: Data from 40 patients at the Granov Russian Scientific Center for Radiology and Surgical Technologies receiving electron beam radiotherapy for primary cutaneous lymphomas were analyzed. As clinical symptoms of radiation-induced skin reactions developed, morphological changes in the affected areas were examined. Dermatoscopic evaluation of skin lesions was performed using a HYPERLINK "https://shop.heine-med.ru/catalog/dermatoskopy/?ysclid=m63jpoace3558532091"Heine Optotechnik (Germany) dermatoscope at tenfold magnification. Confocal spectroscopy was conducted using the VivaScope® 1500 medical device (MAVIG GmbH, Munich, Germany). Instrumental data underwent correlation analysis to identify statistical relationships between dermatoscopic parameters and the severity of radiation-induced skin reactions. Results: Dermatoscopy revealed patterns characteristic of different stages of radiation-induced skin reactions: reticular vascular arrangements in the dermis, brown scaly elements, perifollicular pigmentation, and follicular plugs arranged in rosette-like patterns. Confocal microscopy of radiation dermatitis lesions identified non-stochastic skin changes, including exocytosis (55.3%), spongiosis (63.5%), disorganization of the epidermis (65%), and abnormally structured dermal papillae (85.4%). Low-contrast microvascular cells marking vascular dysfunction in the dermal vascular bed were a specific feature of radiation dermatitis observed regardless of severity. Conclusion: Accurate assessment of skin damage severity can help optimize the management of patients undergoing radiotherapy for primary cutaneous lymphomas. These findings are promising for integrating instrumental evaluation methods into routine clinical practice for early detection of radiation-induced skin changes and predicting disease severity.
- 22 September 2025
- Published by ECO-Vector LLC in Russian Journal of Skin and Venereal Diseases
- Vol. 28 (4) , 381-390
Open AccessDermatoscopic methods for diagnosing radiation-induced skin reactions in patients with primary cutaneous lymphomas undergoing total skin electron beam therapy
Background: Timely diagnosis and assessment of radiation-induced skin reactions remain an important challenge in modern medicine. Imaging techniques can help standardize the clinical evaluation of radiation dermatitis. Aim: The work aimed to evaluate dermatoscopic features and confocal microscopy findings in radiation dermatitis among patients with primary cutaneous lymphomas undergoing radiotherapy, with subsequent analysis of the clinical and morphological characteristics of affected skin areas before treatment and at cumulative doses of 6 Gy, 14 Gy, and 30 Gy, based on macroscopic and dermatoscopic imaging of radiation-induced skin reactions for further comparison. Methods: Data from 40 patients at the Granov Russian Scientific Center for Radiology and Surgical Technologies receiving electron beam radiotherapy for primary cutaneous lymphomas were analyzed. As clinical symptoms of radiation-induced skin reactions developed, morphological changes in the affected areas were examined. Dermatoscopic evaluation of skin lesions was performed using a HYPERLINK "https://shop.heine-med.ru/catalog/dermatoskopy/?ysclid=m63jpoace3558532091"Heine Optotechnik (Germany) dermatoscope at tenfold magnification. Confocal spectroscopy was conducted using the VivaScope® 1500 medical device (MAVIG GmbH, Munich, Germany). Instrumental data underwent correlation analysis to identify statistical relationships between dermatoscopic parameters and the severity of radiation-induced skin reactions. Results: Dermatoscopy revealed patterns characteristic of different stages of radiation-induced skin reactions: reticular vascular arrangements in the dermis, brown scaly elements, perifollicular pigmentation, and follicular plugs arranged in rosette-like patterns. Confocal microscopy of radiation dermatitis lesions identified non-stochastic skin changes, including exocytosis (55.3%), spongiosis (63.5%), disorganization of the epidermis (65%), and abnormally structured dermal papillae (85.4%). Low-contrast microvascular cells marking vascular dysfunction in the dermal vascular bed were a specific feature of radiation dermatitis observed regardless of severity. Conclusion: Accurate assessment of skin damage severity can help optimize the management of patients undergoing radiotherapy for primary cutaneous lymphomas. These findings are promising for integrating instrumental evaluation methods into routine clinical practice for early detection of radiation-induced skin changes and predicting disease severity.
- Open Access
- 11 September 2025
- Published by Publishing House ABV Press in Oncohematology
- Vol. 20 (3) , 27-38
Efficacy of the nivolumab + AVD regimen in the treatment of newly diagnosed classical Hodgkin’s lymphoma: Leningrad Regional Clinical Hospital experience
Aim. To analyze the efficacy and safety of combining nivolumab with AVD chemotherapy (N-AVD) in patients with newly diagnosed classical Hodgkin’s lymphoma in real-world evidence studies.Materials and methods. The retrospective single-center study included 26 patients (14 men, 12 women) with advanced disease stages (IIB with unfavorable prognostic factors according to GHSG (German Hodgkin Study Group) or III–IV according to the Ann Arbor classification). Patients received therapy at the Leningrad Regional Clinical Hospital from March 2023 to February 2025. The N-AVD regimen included nivolumab at a dose of 3 mg / kg (maximum 240 mg), doxorubicin 25 mg / m2, vinblastine 6 mg / m2, and dacarbazine 375 mg / m2 on days 1 and 15 every 28 days. Patients with stage IIB were planned to receive 4 cycles of N-AVD, in case of stages III–IV – 6. Some patients received consolidating proton therapy – 6 (24 %) or 3D conformal radiation therapy – 6 (24 %). The primary endpoint of the study was progression-free survival, and secondary endpoints were the complete remission rate, safety, event-free survival, and overall survival.Results. The complete remission rate was 94 %. With a median follow-up of 11.9 months, 1‑year progression-free survival was 95.7 %, and overall survival – 100 %. The most common adverse events were grade 3–4 neutropenia (46.2 %) and febrile neutropenia (11.5 %). Immune-mediated complications represented by two cases of hypothyroidism and acute pericarditis in one patient.Conclusion. Preliminary results of our study demonstrate the high efficiency of the N-AVD regimen and emphasize the importance of monitoring immune-mediated complications. The advisability of consolidation radiotherapy in patients with complete remission on anti-PD1 monoclonal antibody therapy requires further study. Our study confirms the prospects of using the N-AVD regimen in patients with newly diagnosed classical Hodgkin’s lymphoma, but longer follow-up and a larger sample are needed for conclusions.
- 11 September 2025
- Published by Publishing House ABV Press in Oncohematology
- Vol. 20 (3) , 27-38
Open AccessEfficacy of the nivolumab + AVD regimen in the treatment of newly diagnosed classical Hodgkin’s lymphoma: Leningrad Regional Clinical Hospital experience
Aim. To analyze the efficacy and safety of combining nivolumab with AVD chemotherapy (N-AVD) in patients with newly diagnosed classical Hodgkin’s lymphoma in real-world evidence studies.Materials and methods. The retrospective single-center study included 26 patients (14 men, 12 women) with advanced disease stages (IIB with unfavorable prognostic factors according to GHSG (German Hodgkin Study Group) or III–IV according to the Ann Arbor classification). Patients received therapy at the Leningrad Regional Clinical Hospital from March 2023 to February 2025. The N-AVD regimen included nivolumab at a dose of 3 mg / kg (maximum 240 mg), doxorubicin 25 mg / m2, vinblastine 6 mg / m2, and dacarbazine 375 mg / m2 on days 1 and 15 every 28 days. Patients with stage IIB were planned to receive 4 cycles of N-AVD, in case of stages III–IV – 6. Some patients received consolidating proton therapy – 6 (24 %) or 3D conformal radiation therapy – 6 (24 %). The primary endpoint of the study was progression-free survival, and secondary endpoints were the complete remission rate, safety, event-free survival, and overall survival.Results. The complete remission rate was 94 %. With a median follow-up of 11.9 months, 1‑year progression-free survival was 95.7 %, and overall survival – 100 %. The most common adverse events were grade 3–4 neutropenia (46.2 %) and febrile neutropenia (11.5 %). Immune-mediated complications represented by two cases of hypothyroidism and acute pericarditis in one patient.Conclusion. Preliminary results of our study demonstrate the high efficiency of the N-AVD regimen and emphasize the importance of monitoring immune-mediated complications. The advisability of consolidation radiotherapy in patients with complete remission on anti-PD1 monoclonal antibody therapy requires further study. Our study confirms the prospects of using the N-AVD regimen in patients with newly diagnosed classical Hodgkin’s lymphoma, but longer follow-up and a larger sample are needed for conclusions.
- Open Access
- 11 September 2025
- Published by Autonomous non-profit scientific and medical organization - Questions of Oncology in Voprosy onkologii
- Vol. 71 (4)
Assessment Methods for Cutaneous Manifestations in Mycosis Fungoides
Грибовидный микоз — лимфопролиферативное заболевание, основным и обязательным клиническим проявлением которого является поражение кожи. Пациентам с данной патологией зачастую необходим длительный курс лечения и постоянный медицинский мониторинг, в рамках которого важно корректно и своевременно осуществлять оценку эффективности проводимой терапии, основанную на определении состояния кожи. Это сопровождается рядом трудностей, потому как в настоящее время не представлено стандартизированных руководящих принципов и алгоритмов для детальной оценки поражения кожи пациентов, рекомендованных для применения в клинической практике. Корректная и точная оценка поражений кожи при грибовидном микозе призвана помочь в определении опухолевой нагрузки кожи на момент первичного осмотра, а также в динамике. Задача затрагивает врачей различных специальностей: дерматовенерологов, онкологов, гематологов, радиотерапевтов и химиотерапевтов. В данном обзоре представлены характеристики очагов поражения и клинических форм грибовидного микоза, а также методы оценки площади и морфологии поражения кожи, которые могут найти применение в рутинной практике специалистов.
- 11 September 2025
- Published by Autonomous non-profit scientific and medical organization - Questions of Oncology in Voprosy onkologii
- Vol. 71 (4)
Open AccessAssessment Methods for Cutaneous Manifestations in Mycosis Fungoides
Грибовидный микоз — лимфопролиферативное заболевание, основным и обязательным клиническим проявлением которого является поражение кожи. Пациентам с данной патологией зачастую необходим длительный курс лечения и постоянный медицинский мониторинг, в рамках которого важно корректно и своевременно осуществлять оценку эффективности проводимой терапии, основанную на определении состояния кожи. Это сопровождается рядом трудностей, потому как в настоящее время не представлено стандартизированных руководящих принципов и алгоритмов для детальной оценки поражения кожи пациентов, рекомендованных для применения в клинической практике. Корректная и точная оценка поражений кожи при грибовидном микозе призвана помочь в определении опухолевой нагрузки кожи на момент первичного осмотра, а также в динамике. Задача затрагивает врачей различных специальностей: дерматовенерологов, онкологов, гематологов, радиотерапевтов и химиотерапевтов. В данном обзоре представлены характеристики очагов поражения и клинических форм грибовидного микоза, а также методы оценки площади и морфологии поражения кожи, которые могут найти применение в рутинной практике специалистов.
- Open Access
- 28 July 2025
- Published by Moscow Regional Research and Clinical Institute (MONIKI) in Almanac of Clinical Medicine
- Vol. 53 (2) , 95-105
Comparison of the results of regional chemotherapy alone and in combination with conform radiotherapy in patients with curable pancreatic head cancer and high surgical risk
Rationale: Curative surgery with subsequent adjuvant chemotherapy is the main combination treatment for pancreatic cancer (PC). However, there is the group of patients with resectable tumors who cannot be resected due to severe comorbidities and as such are subjects for palliative anti-tumor treatment. Aim: To evaluate safety and efficacy of regional chemotherapy (RCT) combined with distant radiation therapy (DRT) at daily dose split regimen, compared to RCT alone in PC patients assessed as inoperable. Methods: This retrospective analysis included 71 patients with a resectable ductal adenocarcinoma of the pancreatic head without distant metastases (T2–3N0–2M0), with American Society of Anesthesiologists (ASA) physical status III (a patient with severe systemic disease, inoperable), Eastern Cooperative Oncology Group performance status (ECOG) 1 to 2, who had received RCT alone from 2010 to 2015 (n = 38) or in combination with conform DRT from 2016 to 2024 (n = 33). The subsequent follow-up was censored at February 1, 2025. All patients have received RCT as chemoembolization of the pancreatic head with suspension of gemcitabine and lipiodol followed by intra-arterial infusion of gemcitabine and oxaliplatin during at least 2 cycles. At the 2nd step of treatment, the patients of the main study group received 3D conform daily split-dose DRT (single dose 2 Gy, 4 Gy daily, up to a total physical dose of 50 Gy). Results: The mean age of the patients in the combination chemoradiation therapy group (n = 33) was 70 years, in the RCT alone group (n = 38) 66.5 years (p = 0.8). The study groups were comparable for the ECOG status (p = 0.6), CA 19-9 (p = 0.6), and disease stage (p = 0.6). There were no deaths and adverse events above NCI CTCAE, v. 5.0 grade 2 in both study groups. CTCAE v. 5.0 grade 1–2 toxicities were seen in 31 (93.9%) patients in the RCT + DRT group and in (84.2%) patients of the RCT alone group (p = 0.27), and did not affect the time schedule and dose of treatments. The median time to progression was 7.8 (95% confidence interval [CI] 6.9–8.4) months in the RCT + DRT group and 6.0 (95% CI 5.2–6.3) months in the RCT alone group (p 0.05). The median overall survival was 12.4 (95% CI 10.5–17.8) months and 10.2 (95% CI 8.9–12.2) months, respectively (p = 0.006), and one year survival, 50% and 29%, respectively (p = 0.006). Conclusion: The palliative combination of RCT with daily split-dose DRT is safe and relatively effective treatment and can be viewed as an alternative to surgery in the patients with high surgical risk.
- 28 July 2025
- Published by Moscow Regional Research and Clinical Institute (MONIKI) in Almanac of Clinical Medicine
- Vol. 53 (2) , 95-105
Open AccessComparison of the results of regional chemotherapy alone and in combination with conform radiotherapy in patients with curable pancreatic head cancer and high surgical risk
Rationale: Curative surgery with subsequent adjuvant chemotherapy is the main combination treatment for pancreatic cancer (PC). However, there is the group of patients with resectable tumors who cannot be resected due to severe comorbidities and as such are subjects for palliative anti-tumor treatment. Aim: To evaluate safety and efficacy of regional chemotherapy (RCT) combined with distant radiation therapy (DRT) at daily dose split regimen, compared to RCT alone in PC patients assessed as inoperable. Methods: This retrospective analysis included 71 patients with a resectable ductal adenocarcinoma of the pancreatic head without distant metastases (T2–3N0–2M0), with American Society of Anesthesiologists (ASA) physical status III (a patient with severe systemic disease, inoperable), Eastern Cooperative Oncology Group performance status (ECOG) 1 to 2, who had received RCT alone from 2010 to 2015 (n = 38) or in combination with conform DRT from 2016 to 2024 (n = 33). The subsequent follow-up was censored at February 1, 2025. All patients have received RCT as chemoembolization of the pancreatic head with suspension of gemcitabine and lipiodol followed by intra-arterial infusion of gemcitabine and oxaliplatin during at least 2 cycles. At the 2nd step of treatment, the patients of the main study group received 3D conform daily split-dose DRT (single dose 2 Gy, 4 Gy daily, up to a total physical dose of 50 Gy). Results: The mean age of the patients in the combination chemoradiation therapy group (n = 33) was 70 years, in the RCT alone group (n = 38) 66.5 years (p = 0.8). The study groups were comparable for the ECOG status (p = 0.6), CA 19-9 (p = 0.6), and disease stage (p = 0.6). There were no deaths and adverse events above NCI CTCAE, v. 5.0 grade 2 in both study groups. CTCAE v. 5.0 grade 1–2 toxicities were seen in 31 (93.9%) patients in the RCT + DRT group and in (84.2%) patients of the RCT alone group (p = 0.27), and did not affect the time schedule and dose of treatments. The median time to progression was 7.8 (95% confidence interval [CI] 6.9–8.4) months in the RCT + DRT group and 6.0 (95% CI 5.2–6.3) months in the RCT alone group (p 0.05). The median overall survival was 12.4 (95% CI 10.5–17.8) months and 10.2 (95% CI 8.9–12.2) months, respectively (p = 0.006), and one year survival, 50% and 29%, respectively (p = 0.006). Conclusion: The palliative combination of RCT with daily split-dose DRT is safe and relatively effective treatment and can be viewed as an alternative to surgery in the patients with high surgical risk.